(A) Sonicated chromatin extracts from MCF7 cells treated for 45 min with vehicle (Φ, lane 1), 1 μM Bio A (B, lane 2), Gen (G, lane 3), Res (R, lanes 4–6 and 8) were incubated with antibody to ERα or ERβ. Negative controls were incubated with either non-specific rabbit IgG (lane 5) or no primary antibody (lane 6). As a positive control, chromatin extracts were incubated with Nrf2 antibody (row 3). Bound QR promoter-containing chromatin was detected by PCR analysis using a set of primers surrounding the EpRE (lanes 1–6) or control primers to a region upstream of the EpRE (lanes 7–8). Input chromatin (2%) was also analysed by PCR for a comparison control (row 4). (B) ChIP assays were performed as in (A) using extracts from cells treated for 45 min with vehicle (Φ, lane 1), 1 μM Res (R, lane 2) or 10 μM TBHQ (TQ, lane 4) and incubated with antibody against MafK or ERβ. (C) ChIP assays were performed as in (A) using extracts from cells treated for 45 min with vehicle (Φ, lane 1), 1 μM Gen (G, lane 2), 15 mM NAC (lane 3) or Gen and NAC (G+NAC, lane 4), and incubated with antibody against ERβ or NRF2. The results shown in (A–C) are representative of three or more separate experiments. (D) MDA-MB-231 breast cancer cells were transfected with an expression vector for ERβ along with the reporter gene EpRE-tk-pGL3 and treated for 48 h with the vehicle, 10 μM Gen and/or 10 mM NAC. The cells were also transfected with a Renilla luciferase internal control plasmid to normalize for transfection efficiency. Luciferase activity was measured, and fold activation over cells treated with vehicle is expressed as the average±S.E.M. for three independent experiments.